Grace Therapeutics, Inc. (GRCE)

In the past year, Grace Therapeutics (GRCE) stock has fluctuated between a low of $1.75 and a peak of $3.94.

Information regarding demand seasonality for Grace Therapeutics, Inc.'s products and services was not found in the provided search results.

Grace Therapeutics, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing pharmaceutical products for rare and orphan diseases, operating within the Healthcare sector, specifically in the Biotechnology and Pharma industries. Formerly known as Acasti Pharma Inc., the company changed its name to Grace Therapeutics, Inc. in October 2024. Grace Therapeutics utilizes novel drug delivery technologies to potentially enhance the performance of existing drugs. The company's pipeline includes three clinical-stage drug candidates, each granted Orphan Drug Designation by the FDA, providing seven years of marketing exclusivity in the United States post-launch and is supported by over 40 granted and pending patents. GTX-104 is an intravenous infusion designed to treat aneurysmal Subarachnoid Hemorrhage (aSAH). GTX-102 is an oral mucosal spray of betamethasone intended to improve neurological symptoms of Ataxia-Telangiectasia (A-T). GTX-101 is a topical bioadhesive film-forming polymer for the treatment of pain associated with Postherpetic Neuralgia (PHN).

Grace Therapeutics, Inc. is headquartered in Princeton, New Jersey, United States, and engages in the development and commercialization of pharmaceutical products in Canada.

Information regarding Grace Therapeutics, Inc.'s brand reputation in the past year and any events affecting it was not found in the provided search results.

Information regarding major institutional and individual owners of Grace Therapeutics, Inc. (GRCE) was not found in the provided search results.